ITMCTR2000003364
Recruiting
Phase 1
A randomized, double-blind, prospective clinical study of Weiru Xitong ointment in the treatment of breast hyperplasia
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine0 sitesTBD
ConditionsBreast hyperplasia
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Breast hyperplasia
- Sponsor
- The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients who meet the diagnostic criteria of breast hyperplasia;
- •2\. Patients with previous periodic premenstrual pain had VAS score \>\= 4 and duration \>\= 3 months;
- •3\. Premenopausal women aged 18\-55 years (inclusive);
- •4\. In the past three months, the patients who did not use Chinese and Western drugs to treat breast hyperplasia and relieve breast pain did not use hormone preparations, oral contraceptives and hormone replacement therapy drugs in the past six months;
- •5\. Clinical physical examination of breast, at least one patient with palpable nodule or breast thickening;
- •6\. The local skin of breast is normal without damage;
- •7\. Patients who voluntarily accept the clinical trial and sign the informed consent.
Exclusion Criteria
- •1\. Patients who meet the diagnostic criteria of breast hyperplasia but do not have periodic breast pain symptoms;
- •2\. Patients with mastitis, breast cancer and other breast diseases with surgical indications;
- •3\. Patients who have had breast plastic surgery or breast surgery in the past 3 months;
- •4\. Patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney, hematopoietic system, peptic ulcer or serious diseases (such as tumor or AIDS) affecting their survival, or mental or legal disabilities;
- •5\. Patients with ovariectomy (in whole or in part);
- •6\. Patients with chest pain caused by other diseases;
- •7\. Pregnant or lactating women, or patients with pregnancy plans in the past three months;
- •8\. Patients who are allergic to constitution or known to be allergic to components of the prescription of the drug;
- •9\. According to the judgment of the researchers, other diseases that may reduce the possibility of enrollment or complicate the enrollment, such as changes in the working environment, which may easily lead to loss of interview, as well as insufficient informed consent due to mental and behavioral disorders;
- •10\. Patients who participated in other clinical trials in the past month.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Antibody response after Covid-19 vaccine alongwith Kabasura KudineerCTRI/2021/05/033857Sri Sri Institute of Advance Research
Not yet recruiting
Not Applicable
Antibody response after COVID 19 vaccine provided along with ayurvedic medicine (NOQ19)CTRI/2021/12/038587Sri Sri Institute of Advance Research SSIAR
Completed
Not Applicable
Clinical trial to access change in gut immunity of healthy subjects for efficacy and safety of formulation (s).CTRI/2018/05/013813ITC Life Sciences and Technology Center250
Unknown
Not Applicable
A study to assess energy healing using prana as an add-on therapy for Anxiety.CTRI/2017/11/010646World Pranic Healing Foundation India11
Recruiting
Phase 1
A randomized, controlled, double-blind clinical study of Jiawei Qilang Decoction in the treatment of drug dependent constipatiodrug dependent constipationITMCTR2000003862Shanghai Municipal Hospital of Traditional Chinese Medicine